학술논문

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study

Document Type
Journal
Source
ANNALS OF ONCOLOGY; APR 2022, 33 4, p451-p453, 3p.
Subject
Language
English
ISSN
15698041